News

Ocugen stock rises on Korean licensing deal for gene therapy
Investing.com -- Shares of Ocugen, Inc. (NASDAQ: OCGN) climbed 11.6% following the announcement of a licensing agreement with a leading Korean pharmaceutical company for the rights to OCU400, its gene ...
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more ...